Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25913113 | 0.89 | MEN1 (0.53) | MEN1KMT2ARECQL | |
| SCHEMBL15855122 | 0.88 | MEN1 (0.68) | MEN1KMT2ARECQLCASP2EPHX1 | |
| SCHEMBL29040294 | 0.88 | MEN1 (0.68) | MEN1KMT2ARECQLCASP2EPHX1 | |
| SCHEMBL15855121 | 0.88 | MEN1 (0.68) | MEN1KMT2ARECQLCASP2EPHX1 | |
| SCHEMBL31035882 | 0.88 | MEN1 (0.68) | MEN1KMT2ARECQLCASP2EPHX1 | |
| SCHEMBL21106193 | 0.87 | MEN1 (0.47) | MEN1KMT2AEPHX2RECQLGLP1R | |
| SCHEMBL22861927 | 0.87 | MEN1 (0.47) | MEN1KMT2AEPHX2RECQLGLP1R | |
| SCHEMBL23568885 | 0.87 | EPHX2 (0.48) | EPHX2RECQLGLP1R | |
| SCHEMBL14086890 | 0.87 | KMT2A (0.71) | MEN1KMT2ARECQLCASP2EPHX1 | |
| SCHEMBL25110767 | 0.85 | MEN1 (0.48) | MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885EPHX2 1890/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885EPHX2 1890/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885EPHX2 1890/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885EPHX2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.